California State Teachers Retirement System Boosts Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

California State Teachers Retirement System raised its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRLFree Report) by 1.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 80,541 shares of the medical research company’s stock after buying an additional 980 shares during the period. California State Teachers Retirement System owned about 0.16% of Charles River Laboratories International worth $19,040,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of CRL. Vanguard Group Inc. grew its holdings in Charles River Laboratories International by 0.5% during the third quarter. Vanguard Group Inc. now owns 5,953,860 shares of the medical research company’s stock worth $1,166,837,000 after acquiring an additional 29,482 shares during the period. Kayne Anderson Rudnick Investment Management LLC boosted its position in Charles River Laboratories International by 3.9% in the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,746,101 shares of the medical research company’s stock worth $342,201,000 after purchasing an additional 64,981 shares in the last quarter. Meritage Group LP grew its stake in shares of Charles River Laboratories International by 30.8% during the 4th quarter. Meritage Group LP now owns 1,155,376 shares of the medical research company’s stock worth $273,131,000 after purchasing an additional 271,743 shares during the period. Ariel Investments LLC increased its holdings in shares of Charles River Laboratories International by 1.8% during the 3rd quarter. Ariel Investments LLC now owns 1,066,600 shares of the medical research company’s stock valued at $209,032,000 after purchasing an additional 18,760 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Charles River Laboratories International by 8.9% in the 3rd quarter. Invesco Ltd. now owns 927,895 shares of the medical research company’s stock valued at $181,849,000 after purchasing an additional 75,978 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on CRL shares. TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Evercore ISI upped their price target on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. raised their price objective on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Robert W. Baird reduced their target price on Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, May 10th. Finally, Citigroup lifted their price target on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $258.17.

View Our Latest Analysis on CRL

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $221.62 on Friday. The company has a fifty day simple moving average of $232.22 and a 200-day simple moving average of $231.14. The firm has a market capitalization of $11.42 billion, a price-to-earnings ratio of 26.07, a PEG ratio of 1.99 and a beta of 1.40. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRLGet Free Report) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.05 by $0.22. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 11 EPS for the current fiscal year.

Insider Activity

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the transaction, the executive vice president now directly owns 23,276 shares of the company’s stock, valued at $5,282,953.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

(Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Articles

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLFree Report).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.